SA23 Bruton Tyrosine Kinase Inhibitor (BTKi) Monotherapy for the Treatment of ‘High-Risk’ Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): A Systematic Literature Review (SLR)
Abstract
Authors
L. Mohseninejad L. Walder S. Ubi A. Malyon K. Yang R. Olie